Research
Hormonal
Obesity is associated with a significantly increased risk of kidney cancer, with a 5 kg/m2 higher BMI associated with a 25% higher risk of kidney cancers.
Obesity increases your risk of developing kidney cancer. Maintaining a healthy weight can help reduce this risk.
GoodSupportsHIGH confidence
In a population-based study of 5.24 million individuals from the UK, a 5-kg/m2 higher BMI was associated with a 25% higher risk of kidney cancers, with 10% of all kidney cancers attributable to excess weight.
Why this rating
Based on large population-based studies and meta-analyses.
Source
Obesity and kidney disease: hidden consequences of the epidemic
Csaba P. Kövesdy et al. · Brazilian Journal of Medical and Biological Research · 2017
DOI 10.1590/1414-431x20166075
narrative_reviewCited 17×
Read the paper DOI resolved against Crossref · corpus check 2026-06-10
More from this paper
- High body mass index (BMI) and visceral adiposity are strong, independent risk factors for the development and progression of chronic kidney disease (CKD), end-stage renal disease (ESRD), and obesity-related glomerulopathy (ORG).Good
- Lifestyle interventions involving caloric restriction and increased physical activity reduce the risk of incident chronic kidney disease in overweight or obese diabetic patients by 30% compared to standard education-based follow-up.Good
- Obesity increases the risk of nephrolithiasis (kidney stones) through mechanisms including lower urine pH, increased urinary oxalate, uric acid, sodium, and phosphate excretion, and insulin resistance.Good
Related findings · Hormonal
- Initial treatment for type 2 diabetes should be a combination of metformin and either an SGLT-2 inhibitor or a GLP-1 receptor agonist to achieve cardiorenal protection, rather than monotherapy or older agents like sulfonylureas.Strong
- For patients with specific monogenic obesity syndromes (leptin deficiency, POMC/PCSK1/LEPR mutations), targeted pharmacotherapy (recombinant leptin or setmelanotide) is highly effective and should be prioritized, unlike in polygenic obesity.Strong
- Continued weekly administration of 2.4 mg subcutaneous semaglutide prevents weight regain and promotes further weight loss in adults with overweight or obesity, whereas switching to placebo results in significant weight regain.Strong
This is one finding among thousands. Every one is graded and traced to its source, so you can see what the evidence actually supports. Browse the research →